# DKDPulse Daily Digest — 2026-04-26

_본 도구는 연구·교육 목적의 참고용이며, 임상 의사결정 근거로 사용할 수 없습니다. (This tool is for research and educational reference only and must not be used as a basis for clinical decisions.)_

Total ranked: **10** (top 10)

## SGLT2i  (2)

### Empagliflozin and eGFR Slope in Macroalbuminuric Type 2 Diabetes: A Randomized Trial

- **Source / ID**: pubmed · `MOCK_PM_90000001`
- **Drug class**: SGLT2i
- **Outcomes**: MAKE, UACR, eGFR_slope, hyperkalemia
- **Phenotype**: T2DM_DKD, macroalbuminuric_DKD
- **Novelty score**: `785.417`

> In a 24-month randomized controlled trial of patients with T2DM and macroalbuminuria (UACR >300), empagliflozin 10 mg reduced annual eGFR slope and lowered the composite of major adverse kidney events compared with placebo. Hyperkalemia was rare. Findings align with KDIGO 2024 guideline recommendations.


### Dapagliflozin and Hyperkalemia Risk in DKD: A Pharmacovigilance Cohort

- **Source / ID**: pubmed · `MOCK_PM_90000005`
- **Drug class**: SGLT2i
- **Outcomes**: eGFR_slope, hyperkalemia
- **Phenotype**: T2DM_DKD
- **Novelty score**: `61.954`

> Real-world cohort of 18,000 patients with T2DM-DKD found dapagliflozin associated with a 22% relative reduction in hyperkalemia compared with non-SGLT2 users. eGFR slope was preserved. No new safety signals.


## MRA  (3)

### All-Cause Mortality with Combination SGLT2i + Finerenone in Advanced CKD

- **Source / ID**: pubmed · `MOCK_PM_90000008`
- **Drug class**: MRA, SGLT2i
- **Outcomes**: all_cause_death, hyperkalemia
- **Phenotype**: T2DM_DKD, advanced_CKD
- **Novelty score**: `3562.65`

> Patient-level meta-analysis (n=11,200) of T2DM-DKD with eGFR <30 found a 14% reduction in all-cause death with combined empagliflozin + finerenone vs either alone. Hyperkalemia not increased. Consistent with KDIGO 2024 hierarchical therapy.


### Finerenone in Normoalbuminuric DKD: Post Hoc Analysis of a Phase 3 Trial

- **Source / ID**: pubmed · `MOCK_PM_90000002`
- **Drug class**: MRA
- **Outcomes**: UACR, eGFR_slope, hyperkalemia
- **Phenotype**: T2DM_DKD, normoalbuminuric_DKD
- **Novelty score**: `454.72`

> Among normoalbuminuric patients with type 2 diabetes and eGFR 25-60, finerenone reduced UACR but had only modest effect on eGFR slope. Hyperkalemia incidence was 2.3 times higher than placebo. Authors discuss applicability to KDIGO and KDA guideline updates.


### Esaxerenone Add-on to SGLT2 Inhibitor in T2DM-DKD: A Pilot RCT

- **Source / ID**: pubmed · `MOCK_PM_90000006`
- **Drug class**: MRA, SGLT2i
- **Outcomes**: UACR, eGFR_slope
- **Phenotype**: T2DM_DKD
- **Novelty score**: `163.367`

> Pilot 24-week RCT of esaxerenone added to canagliflozin showed additional UACR reduction of 27% vs SGLT2i alone, with manageable potassium elevation. eGFR slope did not differ. Authors flag dose adjustment per KDIGO advice.


## GLP-1RA  (3)

### Tirzepatide and Albuminuria Reduction in Advanced CKD: A Sub-Study

- **Source / ID**: pubmed · `MOCK_PM_90000003`
- **Drug class**: GLP-1RA, dual-GIP-GLP1
- **Outcomes**: MAKE, UACR, hypoglycemia
- **Phenotype**: advanced_CKD
- **Novelty score**: `1094.75`

> This sub-study of a dual GIP/GLP-1 agonist program enrolled patients with eGFR <30 and overt albuminuria. Tirzepatide reduced UACR by 38% versus placebo over 52 weeks. Severe hypoglycemia was rare. Effect on MAKE was a secondary endpoint.


### Semaglutide vs Dulaglutide in Type 1 Diabetes with Diabetic Kidney Disease

- **Source / ID**: pubmed · `MOCK_PM_90000004`
- **Drug class**: GLP-1RA
- **Outcomes**: UACR, all_cause_death
- **Phenotype**: T1DM_DKD
- **Novelty score**: `116.0`

> Off-label comparison of two GLP-1 receptor agonists in T1DM-DKD demonstrated similar UACR reduction but a numerically lower all-cause mortality signal with semaglutide. Sample size limits inference.


### Liraglutide and Albuminuria in Korean Adults with T2DM: KDA Cohort

- **Source / ID**: pubmed · `MOCK_PM_90000009`
- **Drug class**: GLP-1RA
- **Outcomes**: UACR, hypoglycemia
- **Phenotype**: T2DM_DKD
- **Novelty score**: `51.372`

> KDA registry analysis of 4,300 Korean adults with T2DM and microalbuminuria. Liraglutide associated with 18% UACR reduction at 12 months. Severe hypoglycemia infrequent. Authors note alignment with Korean Diabetes Association 2025 statement.


## dual-GIP-GLP1  (1)

### Retatrutide-Induced Weight Loss and Kidney Function: An Exploratory Analysis

- **Source / ID**: pubmed · `MOCK_PM_90000007`
- **Drug class**: dual-GIP-GLP1
- **Outcomes**: UACR, eGFR_slope
- **Phenotype**: T2DM_DKD, macroalbuminuric_DKD
- **Novelty score**: `290.0`

> Exploratory analysis of a triple agonist trial in T2DM patients with macroalbuminuria. Retatrutide 12 mg yielded marked weight loss but eGFR slope was non-inferior to placebo. UACR change was favorable but underpowered.


## Unclassified  (1)

### A Narrative Review of Cardiometabolic Drugs in Aging

- **Source / ID**: pubmed · `MOCK_PM_90000010`
- **Drug class**: —
- **Outcomes**: —
- **Phenotype**: —
- **Novelty score**: `4.8`

> This non-systematic narrative review covers diet, exercise, and broad metabolic concepts. No specific kidney outcomes or DKD drug analyses are presented.


---

_본 도구는 연구·교육 목적의 참고용이며, 임상 의사결정 근거로 사용할 수 없습니다. (This tool is for research and educational reference only and must not be used as a basis for clinical decisions.)_